Alterity Therapeutics Completes Phase 2 Trial
Ticker: PRNAF · Form: 6-K · Filed: Dec 4, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Dec 4, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, phase-2, biotech
TL;DR
Alterity Therapeutics just finished its Phase 2 trial, big news coming soon!
AI Summary
Alterity Therapeutics Ltd. announced the completion of its Phase 2 clinical trial for its lead drug candidate on December 4, 2024. The trial results are expected to be a significant step in the company's development pipeline.
Why It Matters
The completion of this Phase 2 trial is a crucial milestone for Alterity Therapeutics, potentially paving the way for further clinical development and regulatory submissions for their drug candidate.
Risk Assessment
Risk Level: medium — Clinical trial completion is positive, but the actual results and their implications for future development carry inherent risks.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant and subject of the filing
- December 4, 2024 (date) — Date of the announcement and filing
- Phase 2 clinical trial (clinical_trial) — The subject of the announcement
- Form S-8 (filing) — Registration statement incorporating this 6-K
- Form F-3 (filing) — Registration statement incorporating this 6-K
FAQ
What is the specific drug candidate that completed the Phase 2 trial?
The filing does not specify the name of the drug candidate, only that it is Alterity's lead drug candidate.
When will the results of the Phase 2 clinical trial be announced?
The filing states that the completion of the trial was announced on December 4, 2024, but does not provide a specific date for the announcement of the results.
Which registration statements is this 6-K being incorporated by reference into?
This 6-K is being incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
What is Alterity Therapeutics Limited's principal executive office address?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia.
What is the SIC code for Alterity Therapeutics Ltd.?
The Standard Industrial Classification code is 2834, Pharmaceutical Preparations.
Filing Stats: 192 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-12-04 07:35:12
Filing Documents
- ea0223573-6k_alterity.htm (6-K) — 14KB
- ea022357301ex99-1_alterity.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-105246.txt ( ) — 38KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Alterity Announces Completion of Phase 2 Clinical Trial 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: December 4, 2024 2